Top-Rated StocksTop-RatedNASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis $30.70 -0.60 (-1.92%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$29.72▼$32.0550-Day Range$23.91▼$31.3052-Week Range$21.62▼$44.32Volume2.20 million shsAverage Volume1.84 million shsMarket Capitalization$5.74 billionP/E RatioN/ADividend YieldN/APrice Target$47.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BridgeBio Pharma alerts: Email Address BridgeBio Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside56.1% Upside$47.92 Price TargetShort InterestHealthy12.80% of Float Sold ShortDividend StrengthN/ASustainability-2.31Upright™ Environmental ScoreNews Sentiment0.46Based on 16 Articles This WeekInsider TradingSelling Shares$778,821 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.46) to ($2.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.65 out of 5 starsMedical Sector64th out of 910 stocksPharmaceutical Preparations Industry24th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingBridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.80% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 9.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBridgeBio Pharma has received a 53.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Infigratinib", "Fosdenopterin", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for BridgeBio Pharma is -2.31. Previous Next 2.5 News and Social Media Coverage News SentimentBridgeBio Pharma has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for BridgeBio Pharma this week, compared to 6 articles on an average week.Search Interest18 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $778,821.00 in company stock.Percentage Held by Insiders24.66% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for BridgeBio Pharma are expected to decrease in the coming year, from ($2.46) to ($2.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -9.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -9.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BridgeBio Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About BridgeBio Pharma Stock (NASDAQ:BBIO)BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Read More BBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBIO Stock News HeadlinesAugust 21, 2024 | insidertrades.comBrian C. Stephenson Sells 4,155 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockAugust 21, 2024 | insidertrades.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells 27,389 Shares of StockSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 6 at 7:30 AM | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 6 at 3:51 AM | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Earns Overweight Rating from Analysts at Piper SandlerSeptember 5 at 7:51 PM | msn.comPiper Sandler Initiates Coverage of BridgeBio Pharma (BBIO) with Overweight RecommendationSeptember 5 at 9:49 AM | seekingalpha.comBridgeBio draws bullish view at Piper on potential acoramidis nodSeptember 5 at 2:29 AM | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Rating Reiterated by HC WainwrightSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 4 at 12:03 AM | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)September 4 at 12:03 AM | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma on Acoramidis’s Promising Treatment Efficacy and Best-in-Class PotentialSeptember 3, 2024 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by AnalystsAugust 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma Amidst ATTR-CM Treatment Market DynamicsAugust 31, 2024 | msn.comWhy Is BridgeBio Pharma Stock Trading Higher On Friday?August 31, 2024 | businesswire.comBRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIOAugust 31, 2024 | seekingalpha.comBridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of AcoramidisAugust 30, 2024 | in.investing.comAinylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma risesAugust 30, 2024 | markets.businessinsider.comOptimistic Outlook for BridgeBio Pharma with Acoramidis Leading Market Share ProjectionsSee More Headlines Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BBIO CUSIPN/A CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$47.92 High Stock Price Target$70.00 Low Stock Price Target$37.00 Potential Upside/Downside+56.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-643,200,000.00 Net Margins-207.11% Pretax Margin-210.62% Return on EquityN/A Return on Assets-76.71% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.59 Sales & Book Value Annual Sales$219.12 million Price / Sales26.22 Cash FlowN/A Price / Cash FlowN/A Book Value($5.75) per share Price / Book-5.34Miscellaneous Outstanding Shares187,129,000Free Float140,983,000Market Cap$5.74 billion OptionableOptionable Beta1.07 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Neil Kumar Ph.D. (Age 45)Co-Founder, President, CEO & Director Comp: $1.53MDr. Charles J. Homcy M.D. (Age 76)Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director Comp: $563.2kDr. Frank P. McCormick Ph.D. (Age 74)Co-Founder, Chairman of Oncology & Director Comp: $542.78kDr. Brian C. Stephenson C.F.A. (Age 43)Ph.D., CFO & Secretary Comp: $1.15MDr. Richard H. Scheller Ph.D. (Age 71)Chairman of Research & Development Comp: $509.62kDr. Uma Sinha Ph.D. (Age 66)Chief Scientific Officer Comp: $1.31MGrace RauhVice President of CommunicationsMr. Eli M. Wallace Ph.D. (Age 57)Chief Scientific Officer of Oncology Dr. Thomas Trimarchi Ph.D.Chief Product OfficerDr. Eric Michael David J.D. (Age 52)M.D., Ph.D., Chief Executive Officer of Gene Therapy More ExecutivesKey CompetitorsReata PharmaceuticalsNASDAQ:RETAPerrigoNYSE:PRGOTurning Point TherapeuticsNASDAQ:TPTXAmicus TherapeuticsNASDAQ:FOLDArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsGhisallo Capital Management LLCSold 33,750 shares on 9/4/2024Ownership: 0.018%Neil KumarSold 27,389 sharesTotal: $676,234.41 ($24.69/share)Brian C StephensonSold 4,155 sharesTotal: $102,586.95 ($24.69/share)Perceptive Advisors LLCSold 196,687 shares on 8/16/2024Ownership: 0.649%Algert Global LLCSold 33,558 shares on 8/16/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions BBIO Stock Analysis - Frequently Asked Questions How have BBIO shares performed this year? BridgeBio Pharma's stock was trading at $40.37 on January 1st, 2024. Since then, BBIO stock has decreased by 24.0% and is now trading at $30.70. View the best growth stocks for 2024 here. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.61. BridgeBio Pharma's quarterly revenue was up 32.1% compared to the same quarter last year. When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? BridgeBio Pharma's top institutional investors include Frazier Life Sciences Management L.P. (1.94%), Ensign Peak Advisors Inc (0.88%), The Manufacturers Life Insurance Company (0.82%) and Perceptive Advisors LLC (0.65%). Insiders that own company stock include Global Investors Lp Viking, Neil Kumar, Frank Mccormick, Brian C Stephenson, Randal W Scott, Hannah Valantine, Ronald J Daniels and Douglas A Dachille. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU) and Editas Medicine (EDIT). This page (NASDAQ:BBIO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.